|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Staphylococcal Skin Infections | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| Skin Diseases, Infectious | |||||
| 3 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Gram-Positive Bacterial Infections | |||||
| Skin Diseases | |||||
| Skin Diseases, Bacterial | |||||
| Staphylococcal Infections | |||||
| 4 | Interventions listed in this trial | ||||
| Daptomycin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Novartis | |||||